Skip to main content

Oramed Pharmaceuticals Inc.

ORMP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001176309

In the last 90 days, Oramed Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Oramed Pharmaceuticals Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of ORMP: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders89271−16
Shares6.60M3.66K3.94M−2.66M (−40.3%)
Value$31.0M$17.0K$25.5M−$5.44M (−17.6%)

2 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to ORMP in Q3 2022
InstitutionSharesValue% of portfolio
Walleye Capital LLC78,418$508.0K0.01%
Northwestern Mutual Wealth Management Co1,575$10.0K0.00%
Activest Wealth Management355$2.00K0.00%

Sold out (19)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Not filed for Q3 2022 yet (2)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ORMP in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Urban Wealth Management, LLC2,858$13.0K
Bivin & Associates, Inc.800$4.00K